We identified isoform-specific effects on MFS, RFS, and OS, with low levels of CXCL12-α, -β and -γ significantly correlated with worse MFS and RFS. Most notably, we note that low levels of CXCL12-δ associated with worse OS and showed the same trend for RFS and MFS, despite the fact that CXCL12-δ expression does not correlate with expression of the other isoforms. This relationship is robust and persists even after taking into account CXCL12, CXCR4, and CXCR7 expression FDA approved Drug Library in vitro in multi-gene analysis, indicating the independent prognostic significance of CXCL12-δ. These data provide the first evidence that

CXCL12-δ is expressed in human cancer and correlate with a patient outcome. Expression levels of CXCL12 in breast cancer cell lines generally this website mirror conclusions from the clinical samples that lower levels of CXCL12 correlate with worse prognosis. We found that breast cancer cell lines without metastatic potential (in mouse models) had higher levels of CXCL12 expression than cell lines that metastasize more widely. Studies of CXCL12 in breast cancer focus on secretion of this chemokine by stromal cells in primary and metastatic sites, frequently overlooking effects of CXCL12 produced by cancer cells.

However, epigenetic silencing of the CXCL12 promoter has been reported in breast cancer cells with greater metastatic potential, and re-expressing CXCL12 limits metastatic disease in mouse xenograft models [25]. Our analysis of cell lines may inform likely sources of various CXCL12 isoforms in tumor microenvironments. Breast cancer cells express CXCL12-α, -β, and -γ with very minimal expression of δ, which could indicate that stromal cells are the predominant source of the δ isoform in primary breast cancers. We also note that CXCL12-γ is higher than α and β in our panel of breast cancer cell lines, which is opposite the pattern in primary tumors. Differences between data CYTH4 from cell lines versus tumors may reflect dynamic regulation of CXCL12 isoforms in vivo, greater contributions of stromal cells to overall expression of CXCL12-α and -β in breast tumors, or simply genomic changes as the original

cancer samples were transformed into immortalized cell lines. In addition, CXCL12 levels within the tumor microenvironment may be affected by posttranslational modification, such as cleavage by CD26 or matrix-metalloproteinase-2 [50] and [51]. Isoform-specific differences in expression and breast cancer outcomes suggest distinct functions of individual splice variants of CXCL12 on disease progression. Recent studies have begun to identify unique biochemical properties of CXCL12 isoforms, particularly α, β, and γ. While all isoforms share the same core structure, CXCL12-β, -γ, -δ, -ε, and -φ differ by inclusion of exons that add 4, 40, 51, 1, or 11 additional amino acids, respectively, to the carboxy terminus of the molecule [24].